Abstract: The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Abstract: The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Abstract: The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Abstract: The present invention is directed to novel neuro-attentuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Abstract: A dual PCM liquid suspension is formed by blending a liquid phase change material having a first phase change temperature, a microencapsulated phase change material having a second phase change temperature, a thickening agent, and a surfactant and heating the blended materials for a period of time to form a permanent liquid suspension. PCM liquid suspension behaves as a viscous liquid and may be filled in PCM bottles with conventional liquid filling equipment. The PCM liquid suspension may be preconditioned and stored at a single temperature.

Abstract: The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Abstract: A medical device may comprise a body including a mixture of polyvinylpyrrolidone (“PVP”) and mitomycin. The medical device may be in any size or shape such that the medical device may be inserted into living tissue, including, but not limited to, a lacrimal punctal plug and a stent. The mixture of PVP and mitomycin may be coated on a portion of the medical device, contained within a cavity on the medical device, disposed on the surface of the medical device or configured as part of the medical device such that the mixture of PVP and mitomycin can be delivered to tissue.

Abstract: A medical device may comprise a body including a mixture of polyvinylpyrrolidone (“PVP”) and mitomycin. The medical device may be in any size or shape such that the medical device may be inserted into living tissue, including, but not limited to, a lacrimal punctal plug and a stent. The mixture of PVP and mitomycin may be coated on a portion of the medical device, contained within a cavity on the medical device, disposed on the surface of the medical device or configured as part of the medical device such that the mixture of PVP and mitomycin can be delivered to tissue.

Abstract: The present invention is directed to novel neuro-attentuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Abstract: A medical device may comprise a body including a mixture of polyvinylpyrrolidone (“PVP”) and mitomycin. The medical device may be in any size or shape such that the medical device may be inserted into living tissue, including, but not limited to, a lacrimal punctual plug and a stent. The mixture of PVP and mitomycin may be coated on a portion of the medical device, contained within a cavity on the medical device, disposed on the surface of the medical device or configured as part of the medical device such that the mixture of PVP and mitomycin can be delivered to tissue.

Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Abstract: The present invention is directed to novel neuro-attentuating norketamine (NANKET) compounds according to any one of formulas (I-shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Abstract: An apparatus may be configured to test a beverage, the apparatus may include but is not limited to, a food container, wherein the food container includes a material. An indicator may be combined with at least a portion of the material of the food container, wherein the indicator may be associated with a brand profile that may identify a brand of the food, wherein the indicator may visibly react when the indicator is contacted with the food to show whether the food is identified as the brand of the food, and wherein the visible reaction may be shown on at least the portion of the material of the food container via the indicator combined with at least the portion of the material of the food container.

Abstract: An apparatus is configured to detect a beverage that is contaminated with a substance. The apparatus may include a testing material, wherein the testing material may comprise a cavity having a complementary shape to a molecule associated with the substance. The apparatus may include a taste substance filling the cavity, wherein the taste substance filling the cavity may bleed out into the beverage when the molecule associated with the substance in the beverage replaces the taste substance filling the cavity, wherein a taste of the beverage may change when the taste substance bleeds out into the beverage as an indicator that the substance is present in the beverage.

Abstract: The present invention is directed to novel neuro-attentuating norketamine (NANKET) compounds according to any one of formulas (I-shown below), (I-A) and (I-B)), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Abstract: An apparatus may be configured to test a beverage, the apparatus may include but is not limited to, a food container, wherein the food container includes a material. An indicator may be combined with at least a portion of the material of the food container, wherein the indicator may be associated with a brand profile that may identify a brand of the food, wherein the indicator may visibly react when the indicator is contacted with the food to show whether the food is identified as the brand of the food, and wherein the visible reaction may be shown on at least the portion of the material of the food container via the indicator combined with at least the portion of the material of the food container.

Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.